NEUREN PHARMACEUTICALS LIMITED (NEU)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

NEU

NEU - NEUREN PHARMACEUTICALS LIMITED

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: December
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: 0
Index: ASX200 | ASX300 | ALL-ORDS

LAST PRICE CHANGE +/- CHANGE % VOLUME

$19.00

27 Aug
2025

1.200

OPEN

$18.07

6.74%

HIGH

$19.00

867,697

LOW

$17.83

TARGET
$23.833 25.4% upside
OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGH . AGN . ARX . AVH . BIO . BOT . CSL . CUV . DXB . EOF . GSS . HXL . IDT . IMM . IMU . IVX . LGP . MAP . MSB . MVP . MYX . NUZ . NXS . OCC . OPT . OSL . PAR . PER . PNV . PYC . RAC . RCE . SNT . SPL . TLX . TRP . VIT . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS
NEU: 1
Title FY23
Actual		 FY24
Actual		 FY25
Forecast		 FY26
Forecast
EPS (cps) xxx 111.2 10.2 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx - 10.1% - 90.9% xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A 192.2 xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title 201920202021202220232024
EPS Basic xxxxxxxxxxxxxxx111.2
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx213.2 M
Book Value Per Share xxxxxxxxxxxxxxx286.5
Net Operating Cash Flow xxxxxxxxxxxxxxx-11.3 M
Net Profit Margin xxxxxxxxxxxxxxx66.61 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201920202021202220232024
Return on Capital Employed xxxxxxxxxxxxxxx49.92 %
Return on Invested Capital xxxxxxxxxxxxxxx49.92 %
Return on Assets xxxxxxxxxxxxxxx43.20 %
Return on Equity xxxxxxxxxxxxxxx49.92 %
Return on Total Capital xxxxxxxxxxxxxxx61.70 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-11.3 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201920202021202220232024
Short-Term Debt xxxxxxxxxxxxxxx0 M
Long Term Debt xxxxxxxxxxxxxxx0 M
Total Debt xxxxxxxxxxxxxxx0 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx222 M
Price To Book Value xxxxxxxxxxxxxxx4.36

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201920202021202220232024
Capex xxxxxxxxxxxxxxx0.0 M
Capex % of Sales xxxxxxxxxxxxxxx0.00 %
Cost of Goods Sold xxxxxxxxxxxxxxx0 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx38 M
Research & Development xxxxxxxxxxxxxxx33 M
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

3
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Ord Minnett

08/08/2025

1

Buy

$30.90

62.63%

Sales of Neuren Pharmaceuticals' Daybue via Acadia in the US rose 14% y/y in the June quarter, with 12% rise from new patients and 2% from pricing. This was ahead of consensus and Ord Minnett's forecasts.

The company reiterated guidance for US$380-405m sales in FY25 and flagged it will review this later in the year, while noting the outlook is robust. 

The broker lifted FY25 revenue forecast to US$399m, the upper end of the guidance range, on higher revenue per patient outlook, resulting in EPS upgrades.

Buy. Target rises marginally to $30.90 from $30.80.

Macquarie

xx/xx/xxxx

1

xxxxxxxxxx xx xxxxxxxx xxxx xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

3

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Canaccord Genuity

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Petra Capital

12/08/2025

1

Buy

$31.45

65.53%

Petra Capital notes Neuren Pharmaceuticals' Daybue distributor's 2Q25 Daybue sales were slightly ahead of its forecast and consensus, and FY25 guidance was reiterated at US$380-405m.

Commentary explains the update showed increased penetration in non-COEs with referrals up 75% in 2Q vs 67% in 1Q and the key driver for net patient growth.

Growth is expected to accelerate in the coming quarters and beyond as sales force expansion shows its impact.

EU regulatory approval for Daybue is still expected in 1Q2026, and timeline for a Japanese study remains 3Q25. Buy. Target price $31.45, but forecasts are under review.

FORECAST
Petra Capital forecasts a full year FY25 dividend of 0.00 cents and EPS of 11.90 cents.
Petra Capital forecasts a full year FY26 dividend of 0.00 cents and EPS of 8.10 cents.

Wilsons

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Extra Coverage Research History >

NEU STOCK CHART

FNArena News on NEU

1
FNArena Corporate Results Monitor – 28-08-2025

Aug 28 2025 - Australia
2
Rudi’s View: BlueScope Steel, IGO, GrainCorp, Pilbara Minerals, Santos & More

Aug 14 2025 - Rudi's View
3
Australian Broker Call *Extra* Edition – Aug 13, 2025

Aug 13 2025 - Daily Market Reports
4
Australian Broker Call *Extra* Edition – Aug 12, 2025

Aug 12 2025 - Daily Market Reports
5
Rudi’s View: AI Updates, Hot Favourites & First August Results

Aug 07 2025 - Rudi's View

Latest Pharmaceuticals & Biotech/Lifesciences News

1
Earnings Result Leaves CSL Bloodied

Aug 21 2025 - Australia
2
Renewed Momentum For CSL Shares

Jul 22 2025 - Technicals
3
Treasure Chest: CSL Not A One-Trick Pony

Jul 14 2025 - Treasure Chest
4
The Enigma Surrounding Clinuvel

Jul 03 2025 - Small Caps
5
Rudi’s View: CSL & NextDC

May 08 2025 - Rudi's View
6
Behring Margin Outlook Still Main Game For CSL

Feb 13 2025 - Australia
7
Dr Boreham’s Crucible: Arovella Therapeutics

Aug 29 2024 - Small Caps
8
ResMed’s Margin Upside Excites

Aug 07 2024 - Australia
9
Dr Boreham’s Crucible: Aroa Biosurgery

Jul 29 2024 - Small Caps
10
CSL Shares Breaking Free

Jul 23 2024 - Technicals